Analysts expect Avid Bioservices, Inc. (NASDAQ:CDMO) to report $-0.09 EPS on December, 10.They anticipate $0.18 EPS change or 66.67 % from last quarter’s $-0.27 EPS. After having $-0.06 EPS previously, Avid Bioservices, Inc.’s analysts see 50.00 % EPS growth. The stock decreased 0.40% or $0.02 during the last trading session, reaching $4.93. About 131,355 shares traded. Avid Bioservices, Inc. (NASDAQ:CDMO) has risen 128.25% since November 14, 2017 and is uptrending. It has outperformed by 112.63% the S&P500.
Avid Bioservices, Inc. operates as a contract development and manufacturing organization focusing on the development and cGMP manufacture of biopharmaceutical products derived from mammalian cell culture. The company has market cap of $276.09 million. It provides a range of process development, and cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It currently has negative earnings. The firm produces monoclonal antibodies and recombinant proteins in batch, fed-batch, and perfusion modes; and provides services, including cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing, and regulatory strategy, submission, and support.